
Dimensions
Dimensions –
многотипные данные и
экосистема
цифровой науки
10 сентября
2019
Бакшеева Кристина Игоревна,
Специалист по продуктам
Digital Science Россия и СНГ


Gvt. Review
Equipment
Review Panel
Tech. Trans.
Researcher
Funder
Patent
Grant
Inst.
OA
Publication
Journal Metrics
Scholarly Attention
Dataset
Subject
Journal
DMP
Exp. trial
Media Atten-tion
Software
Protocol
Policy
Ethics
Principal
BioChem Entity

Большая картинка



Экосистема поддержки производства знаний
Digital Science



DIMENSIONS
app.dimensions.ai

Данные в Dimensions и дорожная карта развития

	Q1 2018	Q2 2018	Q3 2018	Q4 2018	2019	End 2019
Publications	★ 89m	+3m	+3m	+3m	100m	+7m
Grants	★ 3.7m	+200k	+200k	+200k	4.5m	+600k
Patents	★ 35m	+500k	+500k	+2m	38m	+80m
Clinical trials	★ 380k	+20k	+20k	+25k	445k	+50k
Policy docs			★ 365k	+20k	422k	+50k
Data sets						★ 800k

1. Data in Dimensions - publication metadata backbone

PUBLICATIONS

- Journal articles, pre-prints and books/book chapters
- 100+ million records based on metadata
- Metadata and citations derived from multiple available databases
- OA tagging
- Rule-based document type identification

JOURNALS / BOOKS

Crossref

PubMed

Europe PMC

PRE-PRINT / OA

bioRxiv beta
THE PREPRINT SERVER FOR BIOLOGY

2019

arXiv.org

ChemRxiv™

RePEc

РОССИЙСКИЙ ИНДЕКС НАУЧНОГО ЦИТИРОВАНИЯ
Science Index

I4OC

Initiative for Open Citations

2. Record enrichment from full text processing

PUBLICATIONS

- Increased discoverability through
  - Full text index
  - Openly available discovery interface
- Highly contextualised - freely available
  - Related grants, publication references, related trials, related patents

Publications	100 million
Source titles covered (Journals, Book series, Preprint server, Conference proceedings)	More than 50,000
Number of links to research organizations (GRID IDs)	158 million
Number of links to researchers (Researcher IDs)	209 million
Number of cited references	1.1 billion
Number of links to grants	11 million
Number of links to funders	17 million
Number of links to clinical trials	891,000

Data in Dimensions - Grants currently

- Project funding
- 4.9 M grants, from +340 funders globally
- $1.6 trillion of funding
- ~$ 0.5 bln. 2018 - >>>
- 210 countries
- Sourcing
  - Direct relationships with funders
  - Data available via APIs
  - Data freely available via websites

Grants	4.6 million
Research funders covered	>340
Total funding amount	USD 1.5 trillion
Average funding amount	USD 403,000
Total amount of funding of projects active in 2019 and beyond	USD 341 billion
Number of links to research organizations (GRID IDs)	4.6 million
Number of links to researchers (Researcher IDs)	6.3 million

Data in Dimensions - Patents currently

PATENTS

- US
- EP
- WIPO
- DE
- RU (Russia, FIPS / EPO)
- CA
- IN
- AU
- GB
- FR
- Hong Kong
- … and more is coming

Patents	38 million
Patent offices covered	10
Number of links to research organizations (GRID IDs)	37 million
Number of cited patent references	227 million
Number of links to publications	10 million
Number of links to grants	165,000
Number of links to funders	221,000

Data in Dimensions - Clinical Trials currently



CLINICAL TRIALS

- ClinicalTrials.gov
- EU-CTR
- UMIN-CTR
- ISRCTN
- ANZCTR
- CHICTR
- NTR - new
- GCTR - new

- … and more are coming

Clinical trials	455,000
Clinical trial registries covered	10
Number of links to sponsors / collaborators (GRID IDs)	1.3 million
Number of links to publications	441,000
Number of links to grants	22,000
Number of links to funders	571,000

Policy Documents – Currently

POLICY DOCUMENTS

Policy documents	421,000
Publishing organizations covered	72
Number of links to publications	1.5 million



Links between the different content sources



Publication

- Publication references
- Publication citations
- Supporting grants
- Patent citations
- Linked clinical trials



Grant

- Resulting publications
- Resulting patents
- Resulting clinical trials



Patent

- Patent references
- Publication references
- Supporting grants
- Patent citations



Clinical trial

- Linked publications
- Supporting grants

POLICY PAPERS

DATA SETS

Dimensions

DIGITAL science

Как это выглядит?

Возьмем статью из, например, PLoS
https://doi.org/10.1371/journal.pone.0037483

Publication - Article

Persistent Systemic Inflammation is Associated with Poor Clinical Outcomes in COPD: A Novel Phenotype

PLoS ONE, 7(5), e37483, 2012
https://doi.org/10.1371/journal.pone.0037483

Authors

Alvar Agustí - Thorax Institute, Hospital Clinic, Institut d'investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona and Centro de investigación en red de enfermedades respiratorias (CIBERES), Barcelona, Spain; Fundación Investigación Sanitaria Illes Balears (FISIB), Palma de Mallorca, Spain

Lisa D. Edwards - GlaxoSmithKline (United States)

Stephen I. Rennard - University of Nebraska Medical Center

15 more

Abstract

BACKGROUND: Because chronic obstructive pulmonary disease (COPD) is a heterogeneous condition, the identification of specific clinical phenotypes is key to developing more effective therapies. To explore if the persistence of systemic inflammation is associated with poor clinical outcomes in COPD we assessed patients recruited to the well-characterized ECLIPSE cohort (NCT00292552). METHODS AND FINDINGS: Six inflammatory biomarkers in peripheral blood (white blood cells (WBC) count and CRP, IL-6, IL-8, fibrinogen and TNF-α levels) were quantified in 1,755 COPD patients, 297 smokers with normal spirometry and 202 non-smoker controls that were followed-up for three years. We found that, at baseline, 30% of COPD patients did not show evidence of systemic inflammation whereas 16% had persistent systemic inflammation. Even though pulmonary abnormalities were similar in these two groups, persistently inflamed patients during follow-up had significantly increased all-cause mortality (13% vs. 2%, p<0.001) and exacerbation frequency (1.5 (1.5) vs. 0.9 (1.1) per year, p<0.001) compared to non-inflamed ones. As a descriptive study our results show associations but do not prove causality. Besides this, the inflammatory response is complex and we studied only a limited panel of biomarkers, albeit they are those investigated by the majority of previous studies and are often and easily measured in clinical practice. CONCLUSIONS: Overall, these results identify a novel systemic inflammatory COPD phenotype that may be the target of specific research and treatment.

Persistent Systemic Inflammation is Associated with Poor Clinical Outcomes in COPD: A Novel Phenotype

Publication Article in **PLoS ONE**, published May 2012

Authors Alvar Agustí, Lisa D. Edwards, Stephen I. Rennard, William MacNee, Ruth Tal-Singer, Bruce E.... **[show more]**

More details

View on publisher site

Summary | Citations | Citing research categories

This is the public page for a publication record in Dimensions, a free research insights platform that brings together information about funding, scholarly outputs, policy, patents and grants.

This publication in **PLoS ONE** has been cited **410 times**. 30% of its citations have been received in the past two years, which is **higher than you might expect**, suggesting that it is currently receiving a lot of interest.

Compared to other publications in the same field, **this publication is extremely highly cited** and has received approximately **62 times more citations** than average.

View more details in Dimensions

410 Citations

123 Recent citations

62.29 Field Citation Ratio

19.17 Relative Citation Ratio

Outcomes in COPD: A Novel Phenotype

Publication Article in **PLoS ONE**, published May 2012

Authors Alvar Agustí, Lisa D. Edwards, Stephen I. Rennard, William MacNee, Ruth Tal-Singer, Bruce E.... **[show more]**

View on publisher site

More details

Summary | Citations | Citing research categories

410 CITATIONS

Dimensions has found a total of **410** citations of this research output. The most recent **3** are shown below. To view the rest you can visit its publication page on Dimensions.

View in Dimensions

Association of platelet count with all-cause mortality and risk of cardiovascular and respiratory morbidity in stable COPD

Article in **Respiratory Research**, published December 2019

Authors: Ashraf Fawzy, Julie A. Anderson, Nicholas J. Cowans, Courtney Crim, Robert Wise, Julie C. Yates,... **[show more]**

Risk factors for lung cancer in COPD – results from the Bergen COPD cohort study

Article in **Respiratory Medicine**, published June 2019

Authors: Gunnar R. Husebø, Rune Nielsen, Jon Hardie, Per Sigvald Bakke, Lorena Lerner, Corina D'Alessandro... **[show more]**

What are the best indicators to assess malnutrition in idiopathic pulmonary fibrosis patients? A cross-sectional study in a referral centre

Article in **Nutrition**, published June 2019

Authors: Stéphane Jouneau, Mallorie Kerjouan, Chloé Rousseau, Mathieu Lederlin, Francisco Llamas-Guttierez... **[show more]**



Persistent Systemic Inflammation is Associated with Poor Clinical Outcomes in COPD: A Novel Phenotype

410

Publication Article in **PLoS ONE**, published May 2012

Authors Alvar Agustí, Lisa D. Edwards, Stephen I. Rennard, William MacNee, Ruth Tal-Singer, Bruce E.... [show more]

More details

View on publisher site

Summary | Citations | Citing research categories

15 CATEGORIES

Research in one subject may be applicable to other areas. The visualization below shows which research fields may be finding this publication relevant, based on a simple count of the subject areas of the publications citing this one.

View in Dimensions



Research Category (FOR code)	%
1102 Cardiorespiratory Medicine and Haematology	75.48
1103 Clinical Sciences	8.65
1117 Public Health and Health Services	8.17
1107 Immunology	2.16
0604 Genetics	1.68
0601 Biochemistry and Cell Biology	0.96
1112 Oncology and Carcinogenesis	0.72
1108 Medical Microbiology	0.48
0605 Microbiology	0.24
1109 Neurosciences	0.24
1115 Pharmacology and Pharmaceutical Sciences	0.24
1116 Medical Physiology	0.24
1199 Other Medical and Health Sciences	0.24
1701 Psychology	0.24
2202 History and Philosophy of Specific Fields	0.24

Publication - Article

Persistent Systemic Inflammation is Associated with Poor Clinical Outcomes in COPD: A Novel Phenotype

PLoS ONE, 7(5), e37483, 2012
https://doi.org/10.1371/journal.pone.0037483

Authors

Alvar Agustí - Thorax Institute, Hospital Clinic, Institut d'investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona and Centro de investigación en red de enfermedades respiratorias (CIBERES), Barcelona, Spain; Fundación Investigación Sanitaria Illes Balears (FISIB), Palma de Mallorca, Spain

Lisa D. Edwards - GlaxoSmithKline (United States)

Stephen I. Rennard - University of Nebraska Medical Center

15 more

Abstract

BACKGROUND: Because chronic obstructive pulmonary disease (COPD) is a heterogeneous condition, the identification of specific clinical phenotypes is key to developing more effective therapies. To explore if the persistence of systemic inflammation is associated with poor clinical outcomes in COPD we assessed patients recruited to the well-characterized ECLIPSE cohort (NCT00292552). METHODS AND FINDINGS: Six inflammatory biomarkers in peripheral blood (white blood cells (WBC) count and CRP, IL-6, IL-8, fibrinogen and TNF-α levels) were quantified in 1,755 COPD patients, 297 smokers with normal spirometry and 202 non-smoker controls that were followed-up for three years. We found that, at baseline, 30% of COPD patients did not show evidence of systemic inflammation whereas 16% had persistent systemic inflammation. Even though pulmonary abnormalities were similar in these two groups, persistently inflamed patients during follow-up had significantly increased all-cause mortality (13% vs. 2%, p<0.001) and exacerbation frequency (1.5 (1.5) vs. 0.9 (1.1) per year, p<0.001) compared to non-inflamed ones. As a descriptive study our results show associations but do not prove causality. Besides this, the inflammatory response is complex and we studied only a limited panel of biomarkers, albeit they are those investigated by the majority of previous studies and are often and easily measured in clinical practice. CONCLUSIONS: Overall, these results identify a novel systemic inflammatory COPD phenotype that may be the target of specific research and treatment.

Persistent Systemic Inflammation is Associated with Poor Clinical Outcomes in COPD: A Novel Phenotype

Overview of attention for article published in PLoS ONE, May 2012

About this Attention Score

In the top 25% of all research outputs scored by Altmetric

MORE...

Mentioned by

1 blog
1 policy source
9 tweeters
6 patents

Citations

410 Dimensions

Readers on

165 Mendeley

What is this page?

SUMMARY | Blogs | Policy documents | Twitter | Patents | Dimensions citations

Title	Persistent Systemic Inflammation is Associated with Poor Clinical Outcomes in COPD: A Novel Phenotype
Published in	PLoS ONE, May 2012
DOI	10.1371/journal.pone.0037483
Pubmed ID	22624038
Authors	Alvar Agusti, Lisa D. Edwards, Stephen I. Rennard, William MacNee, Ruth Tal-Singer, Bruce E. Miller... [show]
Abstract	Because chronic obstructive pulmonary disease (COPD) is a heterogeneous condition, the... [show]

View on publisher site

Alert me about new mentions

TWITTER DEMOGRAPHICS | MENDELEY READERS | ATTENTION SCORE IN CONTEXT

The data shown below were collected from the profiles of **9** tweeters who shared this research output. Click here to find out more about how the information was compiled.



Geographical breakdown

Country	Count	As %
United Kingdom	3	33%
Canada	2	22%
Spain	2	22%
Colombia	1	11%
Unknown	1	11%

Demographic breakdown

Type	Count	As %
Practitioners (doctors, other healthcare professionals)	4	44%
Members of the public	3	33%
Scientists	2	22%

Publication - Article

Persistent Systemic Inflammation is Associated with Poor Clinical Outcomes in COPD: A Novel Phenotype

PLoS ONE, 7(5), e37483, 2012
https://doi.org/10.1371/journal.pone.0037483

Authors

Alvar Agustí - Thorax Institute, Hospital Clinic, Institut d'investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona and Centro de investigación en red de enfermedades respiratorias (CIBERES), Barcelona, Spain; Fundación Investigación Sanitaria Illes Balears (FISIB), Palma de Mallorca, Spain

Lisa D. Edwards - GlaxoSmithKline (United States)

Stephen I. Rennard - University of Nebraska Medical Center

15 more

Abstract

BACKGROUND: Because chronic obstructive pulmonary disease (COPD) is a heterogeneous condition, the identification of specific clinical phenotypes is key to developing more effective therapies. To explore if the persistence of systemic inflammation is associated with poor clinical outcomes in COPD we assessed patients recruited to the well-characterized ECLIPSE cohort (NCT00292552). METHODS AND FINDINGS: Six inflammatory biomarkers in peripheral blood (white blood cells (WBC) count and CRP, IL-6, IL-8, fibrinogen and TNF-α levels) were quantified in 1,755 COPD patients, 297 smokers with normal spirometry and 202 non-smoker controls that were followed-up for three years. We found that, at baseline, 30% of COPD patients did not show evidence of systemic inflammation whereas 16% had persistent systemic inflammation. Even though pulmonary abnormalities were similar in these two groups, persistently inflamed patients during follow-up had significantly increased all-cause mortality (13% vs. 2%, p<0.001) and exacerbation frequency (1.5 (1.5) vs. 0.9 (1.1) per year, p<0.001) compared to non-inflamed ones. As a descriptive study our results show associations but do not prove causality. Besides this, the inflammatory response is complex and we studied only a limited panel of biomarkers, albeit they are those investigated by the majority of previous studies and are often and easily measured in clinical practice. CONCLUSIONS: Overall, these results identify a novel systemic inflammatory COPD phenotype that may be the target of specific research and treatment.

less

Associated data

Persistent Systemic Inflammation is Associated with Poor Clinical Outcomes in COPD: A Novel Phenotype

Showing 1/15: Figure_S1.tif



figshare 1 / 15 Download

Frequency distribution of the percentage of individuals in each group with none, one or more abnormal biomarker values (>95th percentile of the nonsmoker controls) at baseline. For further explanations, see text.

Research Categories

Fields of Research

1102 Cardiorespiratory Medicine and Haematology
1103 Clinical Sciences

Research, Condition, and Disease Categorizations

Chronic Obstructive Pulmonary Disease
Lung
Clinical Research

Health Category (HRCS)

Respiratory
Inflammatory and Immune System

Research Activity Codes (HRCS)

2.1 Biological and endogenous factors
6.1 Pharmaceuticals

Broad Research Areas

Clinical Medicine and Science

Health Research Areas

Clinical

MeSH terms

Biomarkers; C-Reactive Protein; Cohort Studies; Cross-Sectional Studies; Fibrinogen; Humans; Interleukin-6; Interleukin-8; Leukocyte Count; Phenotype; Pulmonary Disease, Chronic
more

External sources

↗ Full text at publisher site
↗ Abstract at PubMed
↗ Full text at PMC

Publication references - 44

Sorted by: Date

Facing a “Slow-Motion Disaster” — The UN Meeting on Noncommunicable Diseases

Lisa Rosenbaum, Daniela Lamas

2011, New England Journal of Medicine - Article

Citations 38 Altmetric 33

Current Controversies and Future Perspectives in Chronic Obstructive Pulmonary Disease

Alvar Agustí, Jørgen Vestbo

2011, American Journal of Respiratory and Critical Care Medicine - Article

Citations 73 Altmetric 3

Systems medicine and integrated care to combat chronic noncommunicable diseases

Jean Bousquet, Josep M Anto, Peter J Sterk, Ian M Adcock, Kian Fan Chung, Josep Roca, Alvar Agusti, Chris Brightling, Anne Cambon-Thomsen, Alfredo Cesario, Son...

2011, Genome Medicine - Article

Citations 135 Altmetric 11

Identification and prospective validation of clinically relevant chronic obstructive pulmonary disease (COPD) subtypes

Judith Garcia-Aymerich, Federico P Gómez, Marta Benet, Eva Farrero, Xavier Basagaña, Àngel Gayete, Carles Paré, Xavier Freixa, Jaume Ferrer, Antoni Ferrer, Josep R...

2011, Thorax - Article

Citations 197 Altmetric 1

Addressing the Complexity of Chronic Obstructive Pulmonary Disease

Alvar Agusti, Patricia Sobradillo, Bartolomé Celli

2011, American Journal of Respiratory and Critical Care Medicine - Article

Citations 123 Altmetric 3

More

Supporting grants - 2

Sorted by: Start Date Funding amount (USD), Funding period

University of Edinburgh/MRC Centre for Inflammation Research
Medical Research Council
to John Iredale
3,286,616
2011 - 2017

Pathobiology of alpha-1-antitrypsin deficency and the serpinopathies
Medical Research Council
to David Arthur Lomas
4,712,147
2011 - 2016

Clinical trial references - 1

Sorted by: Date Trial period

A Multicentre 3 Year Longitudinal Prospective Study to Identify Novel Endpoints and Compare These With Forced Expiratory Volume in 1 Second (FEV1) for Their Ability to Measure and Predict COPD Severity and Its Progression Over Time
GlaxoSmithKline (United Kingdom)
2005 - 2010

Supporting clinical trials - 1

Sorted by: Date Trial period

A Predictive "Molecular Biology Signature" for Diagnosis and Treatment of Chronic Obstructive Pulmonary Disease
Magna Graecia University
2016 - 2018

Publication citations - 408 Show all

Sorted by: Date

Association of platelet count with all-cause mortality and risk of cardiovascular and respiratory morbidity in stable COPD

Ashraf Fawzy, Julie A. Anderson, Nicholas J. Cowans, Courtney Crim, Robert Wise, Julie C. Yates, Nadia N. Hansel

2019, Respiratory Research - Article

Altmetric 6

Risk factors for lung cancer in COPD – results from the Bergen COPD cohort study

Gunnar R. Husebø, Rune Nielsen, Jon Hardie, Per Sigvald Bakke, Lorena Lerner, Corina D'Alessandro-Gabazza, Jeno Gyuris, Esteban Gabazza, Pål Aukrust, Tomas Eag...

2019, Respiratory Medicine - Article

Altmetric 1

The Economic Effect of Early Management in Patients with Early Chronic Obstructive Pulmonary Disease: Results from a Population-Based Nationwide Survey

Young Seok Lee, Kyung Hoon Min, Chin Kook Rhee, Yong Hyun Kim, Seong Yong Lim, Soo-Jung Um, Chang-Hoon Lee, Ki-Suck Jung, Kwang Ha Yoo

2019, Lung - Article

What are the best indicators to assess malnutrition in idiopathic pulmonary fibrosis patients? A cross-sectional study in a referral centre

Stéphane Jouneau, Mallorie Kerjouan, Chloé Rousseau, Mathieu Lederlin, Francisco Llamas-Guttierez, Bertrand De Latour, Stéphanie Guillot, Laurent Vernhet, Benoit ...

2019, Nutrition - Article

Citations 2 Altmetric 2

Novel therapeutic targets and drug development for the precision treatment of COPD

Sara Assaf, Nicola A. Hanania

2019, Expert Review of Precision Medicine and Drug Development - Article

More

Patent citations - 6

Sorted by: Date

Anti-TNF-alpha/CXCL10 Double-Targeting Antibody and Use Thereof

METABOLIC ENGINEERING LABORATORIES Co Ltd - Heun-Soo Kang, So-Hyun Park, Yeong Wook SONG, Ki Chul Shin, Eun Young Lee, Eun Bong Lee, Young Woo Park, Bum-Chan Park,...

Application US - Filed year: 2014

Anti-TNF-α/CXCL10 double-targeting antibody and use thereof

METABOLIC ENGINEERING LABORATORIES Co Ltd - Heun-Soo Kang, So-Hyun Park, Yeong Wook SONG, Ki Chul Shin, Eun Young Lee, Eun Bong Lee, Young Woo Park, Bum-Chan Park,...

Grant US - Granted year: 2018

Bi-specific affinity reagents for cell-lineage-specific TNF-alpha neutralization

DEUTSCHES RHEUMA-FORSCHUNGSZENTRUM BERLIN - Sergei Nedospasov, Andrey Kruglov, Grigory Alexandrovich Efimov

Grant US - Granted year: 2017

BI-SPECIFIC AFFINITY REAGENTS FOR CELL-LINEAGE-SPECIFIC TNF-ALPHA NEUTRALISATION

DEUTSCHES RHEUMA-FORSCHUNGSZENTRUM BERLIN - Sergej Nedospasov, Andrej Kruglov, Grigory Alexandrovich Efimov

Application US - Filed year: 2013

TREATMENT OF SEPSIS AND SEPTIC SHOCK USING GHRELIN AND GROWTH HORMONE

North Shore-Long Island Jewish Research Institute - Ping Wang

Application US - Filed year: 2012

❞ 4

More

Policy Document Citations - 1

Sorted by: Date

Chronic obstructive pulmonary disease in over 16s: diagnosis and management: E: Predicting and preventing exacerbations

2018, National Institute for Health and Care Excellence

Grant

University of Edinburgh/MRC Centre for Inflammation Research

Funder: Medical Research Council (MRC)
Grant number: G0901697

Researchers
John Iredale
PI

Research organization
University of Edinburgh, United Kingdom

Abstract
Inflammation, recognisable in the skin by soreness, redness and swelling following trauma, is a highly evolved defence system that helps our bodies fight invading micro-organisms and repair damage. However if inflammation is not controlled properly it may cause significant illness as is the case in diseases such as asthma and arthritis. Long term (or chronic) inflammatory diseases are amongst the major killers in the UK, for example: Heart and vascular disease, lung and airway disease (for example associated with smoking), chronic liver disease (for example associated with viral infection, alcohol abuse etc) and chronic kidney disease. Unchecked, inflammation also leads to tissue scarring (termed fibrosis) which can critically disrupt the function of organs such as the lung, kidney and liver. Inflammation is also becoming increasingly recognised as an important factor in the development of cancer. Whilst these diseases appear unrelated, there are events common to their development and progression which means that by understanding the biology of inflammation we will be able to develop new approaches to treatment of conditions affecting the lung, heart

more

Similar grants

Sorted by: Start Date Funding amount (USD), Funding period

Thrombo-inflammation in cardiovascular disease European Commission	4,512,616 2019 - 2023
Treatment of inflammation via activation of the mRNA-destabilising protein tristetraprolin Medical Research Council to Andrew R Clark, Andrew Filer, Christopher Buckley	985,280 2019 - 2022
Intracellular nucleic acid sensing and age-related chronic inflammation National Institute of Allergy and Infectious Diseases to SHRUTI SHARMA	481,840 2019 - 2024
Development of TP-317 for the Treatment of Eosinophilic Esophagitis National Institute of Allergy and Infectious Diseases to FRANK SCIAVOLINO	293,722 2019 - 2019
Role of the ADAR1-mediated RNA editing ? RNA sensing axis in sterile inflammation National Institute of Allergy and Infectious Diseases to QINGDE WANG	380,798 2019 - 2024

More

Resulting publications - 364

Sorted by: Publication Date

PD-1 expression is upregulated on adapted T cells in experimental autoimmune encephalomyelitis but is not required to maintain a hyporesponsive state
Iris Mair, Dario Besusso, Louise Saul, Sarju D. Patel, Rahul Ravindran, Rhoanne C. McPherson, Melanie D. Leech, Richard A. O'Connor, Stephen M. Anderton, Richard J. Mellanby
2019, European Journal of Immunology - Article
Altmetric 10 Open Access Add to Library

Share

Details

Funding amount
USD 3.3 M
GBP 2.0 M

Funding period
2011 - 2017
31 Aug 28 Feb

Resulting publications
364

Research Categories

Fields of Research
1102 Cardiorespiratory Medicine and Haematology
1103 Clinical Sciences

Research, Condition, and Disease Categorizations
Digestive Diseases
Lung
Liver Disease

Health Category (HRCS)
Generic Health Relevance
Respiratory
Inflammatory and Immune System

Research Activity Codes (HRCS)
2.1 Biological and endogenous factors
4.1 Discovery and preclinical testing of markers and technologies
5.1 Pharmaceuticals

Broad Research Areas
Clinical Medicine and Science

Health Research Areas
Biomedical

ICRP Cancer Types
Not Site-Specific Cancer

ICRP Common Scientific Outline (CSO)
1.5 Resources and Infrastructure
4.4 Resources and Infrastructure Related to Detection, Diagnosis, or Prognosis
5.7 Resources and Infrastructure Related to Treatment and the prevention of recurrence

Grant profile

DIGITAL science

Patent

Anti-TNF-alpha/CXCL10 Double-Targeting Antibody and Use Thereof

Application US-20160108118-A1

Abstract

The present invention relates to a TNF-α (tumor necrosis factor-alpha)/CXCL-10 (C-X-C motif chemokine 10) double targeting antibody based on the IgG format. Specifically, it was verified that an antibody, in which scFv having a heavy chain variable domain and a light chain variable domain of the CXCL10 specific antibody links to the C-terminus of the heavy chain constant domain of the TNF-α specific antibody, is a bispecific antibody that effectively binds to both TNF-α and CXCL10, and thus the antibody can be useful as a double targeting antibody capable of identifying TNF-α/CXCL10. A composition of the present invention comprises a TNF-α/CXCL-10 double targeting antibody which effectively binds to both TNF-α and CXCL10. The double targeting antibody of the present invention has excellent TNF-α inhibitory activity and osteoclast differentiation inhibitory activity compared with the TNF-α or CXCL10 single targeting antibody. The composition of the present more

Publication references - 4

Sorted by: Date

Persistent Systemic Inflammation is Associated with Poor Clinical Outcomes in COPD: A Novel Phenotype
Alvar Agustí, Lisa D. Edwards, Stephen I. Rennard, William MacNee, Ruth Tal-Singer, Bruce E. Miller, Jørgen Vestbo, David A. Lomas, Peter M. A. Calverley, Emiel Wouters, Courtney Crim, Julie C. Yate...
2012, PLoS ONE - Article
Citations 410 Altmetric 18

Genetics and pathogenesis of multiple sclerosis
R.L. Zuvich, J.L. McCauley, M.A. Pericak-Vance, J.L. Haines
2009, Seminars in Immunology - Article
Citations 55 Altmetric 6

Therapeutic Approaches in Multiple Sclerosis
Heinz Wiendl, Reinhard Hohlfeld
2002, BioDrugs - Article
Citations 155 Altmetric 6

Immune-inflammatory functions of fibroblasts
M Jordana, B Särnstrand, P J Sime, I Ramis
1994, European Respiratory Journal - Article
Citations 69 Altmetric 3

Also published as - 2

Sorted by: Date

Publication number	Publication date	Type
WO-2014199306-A8	2015-12-03	Application
WO-2014199306-A1	2014-11-27	Application

Legal events

Sorted by: Date

Title	Date	Code	Descriptions

Share

Full text

Details

Inventor
Heun-Soo Kang
So-Hyun Park
Yeong Wook SONG
Ki Chul Shin
Eun Young Lee
Eun Bong Lee
Young Woo Park
Bum-Chan Park
Dong Hee Lee
Dong Jin Kim
Seon Ha Yun
Ke Se Lee
Hyun Ju Lee
Kyung Jin Kim
Hee Chan Kim
Seok Ho Yoo
Myeoung Hee Jang
Sell Jang

Original Assignee
METABOLIC ENGINEERING LAB CO LTD

Current Assignee
METABOLIC ENGINEERING LABORATORIES Co Ltd

Legal status
Granted

Expires
-

Document history
Publication date 2016/04/21
Filing date 2014/05/22
Priority date 2013/05/22

Research Categories

Fields of Research
1107 Immunology

Broad Research Areas
Clinical Medicine and Science

Patent Categories

C07K16/24	IPCR
C07K2317/64	CPC
C07K2317/31	CPC
C07K16/46	CPC
C07K2317/565	CPC
C07K2317/76	CPC
A61K2039/505	CPC
C07K2317/92	CPC

Patent profile

DIGITAL science

Clinical Trial

A Predictive "Molecular Biology Signature" for Diagnosis and Treatment of Chronic Obstructive Pulmonary Disease

ClinicalTrials.gov - NCT02633280

Investigators

Luca Gallelli - Magna Graecia University
Principal Investigator

Sponsor/Collaborators

Magna Graecia University, Italy
Sponsor

UCCP, United States
Location

Summary

COPD is an inflammatory disease characterized by enhanced chronic airway and lung inflammatory responses to noxious agents (e.g. smoke, pollutants) and progressive airflow limitation. In COPD patients there is a spillover of peripheral lung inflammation into systemic circulation resulting in increased level of various inflammatory markers such as: IL-1β, IL-6, IL-8, and TNF-α. Diagnosis, now, is based on clinical evaluation and spirometry test and COPD treatment includes the use of LABA, LAMA and corticosteroids. To data no plasmatic marker able to identify the stage of COPD and the response to the treatment have been documented . The aim of this study is to evaluate in COPD patients the role of microRNA as predictive biomarker, of the disease in order to have a signature of miRs typically of COPD Detailed Description Chronic obstructive pulmonary disease (COPD) is a heterogeneous respiratory disorder affecting more than 200 million patients worldwide. It is characterized by enhanced chronic airway and lung inflammatory responses to noxious agents (e.g. smoke, pollutants) and progressive airflow limitation. Both, prevalence and incidence of this

more

Methods

Study phase: -
Condition: COPD

Recruitment information

Gender: All

Clinical trial profile

Resulting publications - 7

Sorted by: Date

Recent updates in chronic obstructive pulmonary disease
Christine Garvey
2016, Postgraduate Medicine - Article

Citations 12 Altmetric 5 Add to Library

Share

Details

Trial period
2016 - 2018
1 Apr 1 Oct

Research Categories

Fields of Research
1102 Cardiorespiratory Medicine and Haematology

Research, Condition, and Disease Categorizations
Biotechnology
Chronic Obstructive Pulmonary Disease
Lung
Clinical Research
Genetics

Health Category (HRCS)
Respiratory

Research Activity Codes (HRCS)
2.1 Biological and endogenous factors
4.1 Discovery and preclinical testing of markers and technologies

Broad Research Areas
Clinical Medicine and Science

Health Research Areas
Biomedical

External sources

↗ Orig. Description

Ассоциированные данные
ASSOCIATED DATA (DATA SETS)

OPEN ACCESS

Closed	78,286,288
All OA	23,435,361
Bronze	11,734,541
Pure Gold	3,844,933
Green, Submitted	3,569,215
Hybrid	2,677,822
Green, Published	1,156,938
Green, Accepted	451,912

PUBLICATION TYPE

Article	21,470,574
Proceeding	765,161
Chapter	614,935
Preprint	404,396
Monograph	98,387

COUNTRY/TERRITORY

Russia	1,128,083

OPEN ACCESS

Closed	940,026
All OA	188,057

Name	↓ Publications Relevant	FCR Mean	RCR Mean	Altmetric ... % mentio...	Altmetric Att... Median
Elsevier	2,371,532	2.23	1.55	20.2	3.0
Springer Nature	2,152,420	2.02	1.23	28.5	3.0
Wiley	1,615,358	2.42	1.23	25.6	3.0
Oxford University Press (OUP)	1,015,958	2.52	1.40	26.4	3.0
Taylor & Francis	542,156	1.50	0.82	24.2	3.0
Wolters Kluwer	515,816	2.10	1.29	29.6	3.0
BMJ	486,530	1.39	0.83	15.6	3.0
Institute of Electrical and Electronics Engineers (IEE...	435,286	2.14	0.94	12.2	3.0
IOP Publishing	413,531	1.21	0.81	17.4	2.0
Cambridge University Press (CUP)	390,024	1.29	0.93	9.9	3.0
FapUNIFESP (SciELO)	349,593	0.73	0.43	10.6	1.0
SAGE Publications	343,813	1.69	0.85	25.1	3.0
American Physical Society (APS)	262,393	3.37	0.67	36.5	1.0
Public Library of Science (PLoS)	257,460	2.32	1.16	65.2	3.0
De Gruyter	241,342	0.54	0.46	4.1	2.0

SCIENTIFIC DATA

Amended: Addendum

OPEN

SUBJECT CATEGORIES

» Research data

» Publication characteristics

Comment: The FAIR Guiding Principles for scientific data management and stewardship

Mark D. Wilkinson *et al.*#

Received: 10 December 2015

Accepted: 12 February 2016

Published: 15 March 2016

There is an urgent need to improve the infrastructure supporting the reuse of scholarly data. A diverse set of stakeholders—representing academia, industry, funding agencies, and scholarly publishers—have come together to design and jointly endorse a concise and measureable set of principles that we refer to as the FAIR Data Principles. The intent is that these may act as a guideline for those wishing to enhance the reusability of their data holdings. Distinct from peer initiatives that focus on the human scholar, the FAIR Principles put specific emphasis on enhancing the ability of machines to automatically find and use the data, in addition to supporting its reuse by individuals. This Comment is the first formal publication of the FAIR Principles, and includes the rationale behind them, and some exemplar implementations in the community.

Findable, **A**ccessible, **I**nteroperable, **R**eusable

https://www.go-fair.org/fair-principles/

figshare MY DATA BROWSE UPLOAD Christopher George



Download (8.05 MB) Cite

OTU robustness, reproducibility & ecological consistency

figshare MY DATA BROWSE UPLOAD Christopher George



Download (747.27 kB) Cite

Zharina Pelea, Maria; Johnson, Wesley; Davidson, Zoe (2015): WT Tim-1 moves away from the nascent IS after APC stimulation. figshare.

https://dx.doi.org/10.5072/FK2.figshare.2001555

Retrieved 15:24, Aug 14, 2015 (GMT)

figshare search on figshare Browse Upload Sign up Log in

	A	B	C	D	E	F	G
1	key	name	smiles	mpC	csid	link	source
2	1	2-(2,4-dinitrobenzyl)pyridine	c1ccnc(c1)Cc2ccc(cc2[N+](=O)[O-])[N+](=O)[O-]	92	64018	http://www.alfa.com/en/GP100W.pgm?DSSTK=B24192	Alfa Aesar
3	2	2-(1-piperidinyl)aniline	c1ccc(c(c1)N)N2CCCCC2	46	403764	http://www.alfa.com/en/GP100W.pgm?DSSTK=A13073	Alfa Aesar
4	3	2-(1-piperazinyl)pyrimidine	c1cnc(nc1)N2CCNCC2	33	80080	http://www.alfa.com/en/GP100W.pgm?DSSTK=L15884	Alfa Aesar
5	4	2-(1-piperazinyl)phenol	c1ccc(c(c1)N2CCNCC2)O	125	63701	http://www.alfa.com/en/GP100W.pgm?DSSTK=B20252	Alfa Aesar
6	5	2-(1-cyclohexenyl)ethylamine	C1CCC(=CC1)CCN	-55	69388	http://www.alfa.com/en/GP100W.pgm?DSSTK=L08261	Alfa Aesar
7	6	2-(1-boc-4-piperidinyloxy)-n-methylacetamide	CC(C)(C)OC(=O)N1CCC(CC1)OCC(=O)NC	95	25027436	http://www.alfa.com/en/GP100W.pgm?DSSTK=H32990	Alfa Aesar
8	7	2-(1-boc-4-piperidinyloxy)-n-cyclopropylacetamide	CC(C)(C)OC(=O)N1CCC(CC1)OCC(=O)NC2CC2	86	25027435	http://www.alfa.com/en/GP100W.pgm?DSSTK=H32069	Alfa Aesar

Explore more content

Sheet1 Sheet2 Sheet3

BradleyMeltingPointDataset.xlsx (2.12 MB) MD5: 6a4690f289e8377ef333208f846bcae1

Cite Download (2.12 MB) Share Embed + Collect (you need to log in first)

Jean-Claude Bradley Open Melting Point Dataset

Version 2 20.05.2014, 19:29 by Jean-Claude Bradley, Antony Williams, Andrew Lang

43968 views 2143 downloads 2 citations

Jean-Claude Bradley's Legacy Dataset of Open Melting Points. 28,645 measurements including those found to be incorrect (marked as 'do not use'). csid corresponds to Chemspider ID.

figshare search on figshare Browse Upload Sign up Log in

Create co-occurence networks

This notebook creates co-occurence networks and exports them to .gexf-files, either at the start of a new book or chapter or one network for all selected books and chapters.

User variables

```
In [22]: # which Bible passages to create co-occurence networks for
         # -1 matches the last chapter/verse. Useful when selecting a
         passages = {
             "Samuel_I": [1,1,-1,-1]
         }

         # what range the co-occurence networks should have
```

Explore more conten

currences with filter and verses.ipynb (18.69 kB)

Cite Download all (83.7 MB) Share Embed + Collect (you need to lo

Using social co-occurrence networks to analyze Biblical narrative

14.06.2016, 18:26 by Frederik de Vree

Results and code of MSc thesis Artificial Intelligence on VU Amsterdam, wit

"Using social co-occurrence networks to analyze Biblical narrative" by Frede

figshare search on figshare Browse Upload Sign up Log in



01-Allosaur tooth rooted.stl (6.95 MB)

Cite Download (6.95 MB) Share Embed + Collect (you need to log in first)

UWO-VPC-2013.001-Allosaur tooth rooted

21.02.2014, 21:55 by Joseph Peterson

Scanned with a Nextengine Desktop 3D Scanner and Scan Studio Pro (NextEngine) on high resolution settings. Model composed of 72,989 vertices and 145,758 faces. Saved as an *.stl file in MeshLab (v.1.3.2).

figshare search on figshare Browse Upload Sign up Log in



om-google-roman-archa… .gephi (291.99 kB) MD5: c73cec0fbe435f491f3b9cc

Cite Download all (26.6 MB) Share Embed + Collect (you need to log in first) 1 / 13

Mapping the Structure of the Archaeological Web

Version 2 29.04.2014, 17:03 by Shawn Graham

718 views 58 downloads 0 citations

A fileset to accompany an article in a special issue of *Internet* Archaeology. In this article, I map the structure of the web to understand the context of archaeological blogging.

4

figshare

zenodo

DRYAD

PANGAEA.



Papers from Russian Universities linking to datasets on Figshare (Dimensions)



Papers from Russian Universities linking to datasets on Figshare



Characterization of the mitochondrial genome of the MAX1 type of cytoplasmic male-sterile sunflower

Maksim S. Makarenko, Alexander V. Usatov, Tatiana V. Tatarinova, Kirill V. Azarin, Maria D. Logacheva, Vera A. Gavrilova and Renate Horn

BMC Plant Biology 2019 **19 (Suppl 1)** :51
https://doi.org/10.1186/s12870-019-1637-x | © The Au
Published: 15 February 2019

Affiliated with

1. Institute for Information Transmission Problems, Moscow, Russia
2. Skolkovo Institute of Science and Technology, Moscow, Russia

Abstract

Funding

The study was supported by the Ministry of Education and Science of Russia project no. 6.929.2017/4.6. Analytical work was carried out on the equipment of centers for collective use of Southern Federal University "High Technology." The publication costs are funded by the Ministry of Education and Science of Russia project no. 6.929.2017/4.6.

Availability of data and materials

The HA89 fertile line genome is available at https://doi.org/10.6084/m9.figshare.7265648.v1; this sequence will later be deposited to NCBI GenBank. The complete mitochondrion sequence of CMS line HA89(MAX1) has been deposited to GenBank under the accession number MH704580.1.

www.overleaf.com

Here we provide a selection of academic journal templates for articles and papers which automatically format your manuscripts in the style required for submission to that journal. Thanks to the partnerships we're building within the publishing community, you can also now submit your paper directly to a number of journals and other editorial and review services via the publish menu in the editor.





files
styles
GSA-journal-template.tex
example-bibliography.bib
example-figure.png
genetics.bst
gsajnl.cls

DOWNLOAD AS ZIP

Save to Dropbox

Your Abstract

In addition to the guidelines provided in the example abstract above, your abstract should:

- provide a synopsis of the entire article;
- begin with the broad context of the study, followed by specific background for the study;
- describe the purpose, methods and procedures, core findings and results, and conclusions of the study;
- emphasize new or important aspects of the research;
- engage the broad readership of GENETICS and be understandable to a diverse audience (avoid using jargon);
- be a single paragraph of less than 250 words;
- contain the full name of the organism studied;
- NOT contain citations or abbreviations.

Introduction

For the introduction, authors should be mindful of the broad readership of the journal. The introduction should set the stage for the importance of the work to a generalist reader and draw the reader in to the specific study. The scope and impact of the work should be clearly stated.

In individual organisms where a mutant is being studied, the

Template for preparing your submission to *GENETICS* using Overleaf

Author One[*,1], **Author Two**[†], **Author Three**[‡], **Author Four**[§] **and Author Five**[**]
[*]Author one affiliation, [†]Author two affiliation, [‡]Author three affiliation, [§]Author four affiliation, [**]Author five affiliation

ABSTRACT The abstract should be written for people who may not read the entire paper, so it must stand on its own. The impression it makes usually determines whether the reader will go on to read the article, so the abstract must be engaging, clear, and concise. In addition, the abstract may be the only part of the article that is indexed in databases, so it must accurately reflect the content of the article. A well-written abstract is the most effective way to reach intended readers, leading to more robust search, retrieval, and usage of the article.
Please see additional guidelines notes on preparing your abstract below.

KEYWORDS Keyword; Keyword2; Keyword3; ...

This *Genetics* journal template is provided to help you write your work in the correct journal format. Instructions for use are provided below.

Guide to using this template in Overleaf

This template is provided to help you prepare your article for submission to the *Genetics*.

Author Affiliations

For the authors' names, indicate different affiliations with the symbols: *, †, ‡, §. After four authors, the symbols double, triple, quadruple, and so forth as required.

Your Abstract

In addition to the guidelines provided in the example abstract above, your abstract should:

- provide a synopsis of the entire article;
- begin with the broad context of the study, followed by specific background for the study;
- describe the purpose, methods and procedures, core findings and results, and conclusions of the study;
- emphasize new or important aspects of the research;
- engage the broad readership of GENETICS and be understandable to a diverse audience (avoid using jargon);
- be a single paragraph of less than 250 words;
- contain the full name of the organism studied;
- NOT contain citations or abbreviations.

Introduction

For the introduction, authors should be mindful of the broad readership of the journal. The introduction should set the stage for the importance of the work to a generalist reader and draw the reader in to the specific study. The scope and impact of the work should be clearly stated.

In individual organisms where a mutant is being studied, the rationale for the study of that mutant must be clear to a geneticist not studying that particular organism. Similarly, study of particular phenotypes should be justified broadly and not on the basis of interest for that organism alone. General background on the importance of the genetic pathway and/or phenotype should be provided in a single, well-reasoned paragraph near the beginning of the introduction.

Authors are encouraged to:

- cite the supporting literature completely rather than select a subset of citations;
- provide important background citations, including relevant review papers (to help orient the non-specialist reader);
- to cite similar work in other organisms.

doi: 10.1534/genetics.XXX.XXXXXX
Manuscript compiled: Monday 25th July, 2016%
[1]Please insert the affiliation correspondence address and email for the corresponding author. The corresponding author should be marked with a '1' in the author list, as shown in the example.

Прямая интеграция для подачи статей в журналы издательств



Интеграция с сервисами препринтов и крупнейшими репозиториями




IEEE
SPRINGER NATURE
SPIE.
PeerJ
OXFORD UNIVERSITY PRESS
GSA Genetics Society of America
ASBMB
AGU American Geophysical Union
OSA The Optical Society
ASCE
PNAS
F1000Research
bioRxiv THE PREPRINT SERVER FOR BIOLOGY
figshare credit for all your research
MENDELEY
editage by CACTUS
Rubriq
zotero
AJE
AXIOS REVIEW
bioedit
enago
em
SCHOLARONE™
eJournalPress
IEEE Collabratec

CERN Authoring

CERN Authoring offers modern authoring tools to CERN members that focus on collaboration, ease of use and integration and cover the needs of the High Energy Physics community.

Get in touch with CERN Authoring at authoring@cern.ch, join our community forum and visit the CERN Service Portal for help & support.

Overleaf

Overleaf is an online LaTeX and Rich Text collaborative editor, reviewing and publishing tool.

Key features

- Pure LaTeX editor
- Rich Text editor
- Real-time collaboration
- Real-time PDF preview
- Author comments
- Track changes
- Version control w/ Git access
- Export as PDF & LaTeX

FAQ

- How can I claim my CERN account on Overleaf?
- How can I get help on how to use Overleaf?
- How can I access the Overleaf v1 dashboard?
- How can I migrate my ShareLaTeX account to Overleaf?

Go to Overleaf »

“Big picture” of research and innovation – CONTEXTUALIZED



ПРИМЕРЫ

Dimensions

DIGITAL science

Shaping Research Strategy Example: Aramids



Благодарю за Ваше внимание!

k.baksheeva@digital-science.com

i.osipov@digital-science.com

Dimensions

DIGITAL science